Therapy for nonalcoholic fatty liver disease.
Moseley
Richard H
RH
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D002756:Cholagogues and Choleretics / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005234:Fatty Liver / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005998:Glycine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D051379:Mice; D010080:Oxazoles / Q000627:therapeutic use; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists; D051381:Rats; D045162:Thiazolidinediones / Q000627:therapeutic use*; D016896:Treatment Outcome; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use
D000975:Antioxidants; D002756:Cholagogues and Choleretics; D000960:Hypolipidemic Agents; D010080:Oxazoles; D047492:Peroxisome Proliferator-Activated Receptors; D045162:Thiazolidinediones; D014810:Vitamin E; D014580:Ursodeoxycholic Acid; D005998:Glycine; C500085:muraglitazar